

Keyword Index for Volume 88

- 19q 1914
2-(4-aminophenyl)benzothiazole 470, 599
5'-deoxyfluorouridine 957
5-fluorouracil 624, 957, 1507, 1669
5HT₃ antagonists 1823
5q21 region 1925
7q31 region 1909, 1925
8p21 270
- α 1-adrenoceptor antagonists 1615
 α 5 β 1 integrin 327
 α -fetoprotein 1878
 α -particle emitter ²¹³Bi 944
A33 antibody 937
acrylamide 84
adaptive intrapatient dose adjustment 814
additivism 1281
adenocarcinoma 63, 1229, 1886
adenocarcinoma of the cardia 401
adenoma size 1866
adenomatous polyposis coli (APC) 202
adenovirus 1492
adhesion molecules 1772
adjuvant therapy 1859
adrenal gland 1746
advanced non-small-cell lung cancer 342
adverse drug reaction 1157
adverse effects 1510
Africa 1
age 487, 839
agmatine 613
ALA derivatives (ALA hexyl ester) 432
alcohol 58, 366, 675, 1044, 1702
alkylating agents 1828
alternative splicing 918
AMD473 1128
amelanotic melanoma 1462
amifostine 754
aminolevulinic acid (ALA) 432
anaemia 988, 1851
anal cancer 1352
androgen-independent 822
anger 658
angiogenesis 163, 307, 478, 537, 553, 711, 718, 796, 1424, 1453, 1484, 1727, 1900
angiogenesis inhibitors 965
angiogenic factor 307
Annexin V 1301
antiapoptosis 902
antibiotics 1012
antibody directed enzyme-producing therapy (ADEPT) 937
antibody pretargeting 996
anticancer drugs 803
anticancer effect 1948
Antiemetics 1823
antineoplastic agents 1793
antioxidants 940, 1381
antitumoral agents 940
antivascular 1844
anti-VEGF mAb 1979
anxiety 658
Apaf-1 1785
APC 1932
Apc^{-/+} mice 1480
apheresis 396
aponecrosis 1987
apoptosis 115, 153, 163, 210, 223, 298, 463, 487, 586, 748, 754, 788, 910, 918, 1077, 1143, 1301, 1527, 1584, 1615, 1649, 1763, 1785, 1948, 1971
apoptosis induction 1800
areca 366
arginase 613
arginine 613
arginine decarboxylase 613
aromatase 630
aryl hydrocarbon receptor 599
aspirin 672, 1480
association 1920
atrophic gastritis 1239
augmentation 832
autocrine 567
autophagy 1277
axillary nodes 96
Axin 1734
- β -catenin 206, 740, 1755
B7.1 424
B7.2 424
bak 1584
Barrett's oesophagus 1271
BAX 586, 848
BCL-2 848
Bcl-X_L 910
Belgium 560
benign prostate hyperplasia 928
bereavement 1698
bilateral testicular neoplasms 828
bile acids 748
biochemotherapy 424
biological markers 1239, 1271, 1721
bisphosphonates 1631, 1971
black gold miners 1361
bladder cancer 84, 586, 1492, 1932
bleomycin 1763
blood supply 291
blood vessel invasion 1900
BMI 36
BNIP3L 270
body mass 1038
body mass index 1388
body weight 679
bone infiltration 1105
bone marrow 855
bone metastasis 195, 1318
bone resorption 1318
bone scan 195
bone sialoprotein 396
bosentan 788
Bowen's disease 1375
BRAF 1403
brain tumours 1889
BRCA1 1256, 1285
BRCA1-defective cells 1285
BRCA1 protein 1263
BRCA2 933, 1256
breast 362, 702, 1339
breast and prostate cancer 438
breast cancer 50, 58, 125, 277, 406, 470, 491, 574, 630, 675, 711, 832, 863, 871, 944, 1047, 1065, 1077, 1084, 1091, 1168, 1207, 1256, 1310, 1318, 1358, 1400, 1587, 1708, 1900
breast cancer diagnosis 832
breast cancer resistance protein 879
breast cancer risk 1394
breast cancer screening 1708
breastfeeding 1035
breast hereditary cancer 1285
breast imaging 4
breast implants 832
breast self-examination 1047
breast tumours 102, 579, 832
bromodeoxyuridine 895
Burkitt's lymphoma 1566
butyrate 748
bystander effect 767
- c-erbB-2 711
c-fos 1143
c-kit 1157
c-myc 1143
C4.4a 579
CA-19-9 1248
calcitonin 1537
cancer immunotherapy 1292
cancer mortality 689
cancer registries 1693
cancer susceptibility 487
cancer therapy 613
capecitabine 782
CAR 1411
carbonic anhydrase 1065
carcinogenesis 733, 740, 1217, 1501, 1734
carcinosarcoma 654
cardiotoxicity 1507
carotenoid 1381
case-control studies 58, 373, 672, 1702
caspase-3 1615
caspase-8 1527
caspase-9 1971
caspase-activated DNase 210
caspases 910, 1800
catabolism 613
caveolin-1 1234
CCR2 855
CD24 231
CD26/DPPIV 455
CD34 selection 1874
CD40 1527
CD40L 586
CDH1 1932
CDKN2A 1920
CEA 1248
cell cycle 455, 1417, 1470, 1649
cell cycle arrest 388, 754
cell death 613
cell death assays 125
cell invasion 1111
cell nucleolus 1942
cell proliferation 775
cervical cancer 63, 1054, 1095, 1213, 1388, 1584, 1713
cervical cancer screening 42, 560, 1570
CGH 1578
chemokines 855, 1772
chemoprevention 803, 1480
chemoradiation 1352
chemoradiotherapy 18
chemoresistance 624
chemotherapy 25, 167, 181, 187, 491, 496, 654, 1025, 1084, 1180, 1185, 1199, 1248, 1352
Child Health Questionnaire 1185
childhood cancer 373, 382, 1035, 1661
childhood leukaemia 695, 775, 1939
childhood solid tumours 1370
children 1693
chimeric 1119
chimeric receptor 1292
CHO-K1 327
cholecystectomy 79
chromogranin 1746
chromosome 9 1578
chromosome aberrations 548, 1939
chronic disease 1851
chronic lymphatic leukaemia 74
chronic lymphocytic leukaemia 593
circumferential resection margin 1017
circumin 1480
cirrhosis 733
CISH 1587

- cisplatin 25, 814, 951, 1199, 1285, 1516
 cisplatin-resistance 1327
 citrulline 613
 clear cell ovarian 1578
 clinical trials 1128, 1661
 CML 983
 cohort study 684
 collagen crosslinks 1105
 collateral sensitivity 1963
 collusion 839
 colon 895
 colon adenomas 79, 748
 colon cancer 79, 530, 788, 803, 937, 1445, 1755, 1995
 colorectal cancers 206, 413, 648, 726, 1038, 1044, 1598, 1859, 1909
 combination chemotherapy 1942
 comet assay 895
 communication 666
 communication skills 502, 658
 comparative genomic hybridisation 1914
 confocal microscopy 146
 cost-effectiveness 31
 costimulatory molecules 1527
 coumarin derivatives 1111
 COX inhibitors 1143
 COX-2 574, 1631, 1217
 CpG island 109, 413
 CpG methylation 521
 CPG2 1622
 CPT-11 1979
 crossreactivity 202
 CXCR-4 1631
 cyclin 1417
 cyclin B1 257
 cyclin D1 257
 cyclin D2 1560
 cyclin-dependent kinase inhibitors 1277
 cyclin E 1914, 1956
 cyclooxygenase-2 1445, 1598
 cyclosporin 973
 CYFRA 21-1 1894
 CYP17 933
 CYP1A1 599
 CYP3A4 928
 CYP19 675
 CYP1B1 675
 cystine 951
 cytodagnosis 1740
 cytokines 630, 1207, 1772
 cytological techniques 1883
 cytology 702
 cytology performance 1570
 cytoprotection 754
 cytoskeleton 1793
 cytotoxic medium conditioning 447
 Dacarbazine 132, 496
 darbepoetin alpha 1851
 decision making 1675
 delayed reproductive death 548
 deletion spectrum 90
 demethylation 1560
 denaturing HPLC 1889
de novo carcinoma 1866
 deoxycytidine kinase 1963
 depression 658
 deprivation 613
 desmoid tumour 645
 detection 1358
 DFF 210
 DFF-B 210
 DHPLC 270
 diagnosis 354, 516, 839, 1175, 1239, 1358, 1878
 diet 84, 689, 1381, 1682
 DMXAA 1160, 1844
 DNA adducts 470
 DNA damage 599
 DNA double strand breaks 1251
 DNA fragmentation factor 210
 DNA methylation 1932
 DNA-ploidy 31
 DNA repair 1939
 DNA replication 895
 DNA sequence 1403
 docetaxel 11, 1168, 1335, 1339, 1669
 documentation 839
 dorsal root ganglion 1942
 doxorubicin 1281, 1285, 1956
 DPC4 420
 drug resistance 775, 951, 973, 983, 1793, 1956
 dwelling time 1866
 dysadherin 726
 dysphagia 18
 dystroglycan 579
 E1B-deleted 1492
 early breast cancer 96
 E-cadherin 718, 1727
 ECM 1470
 EGF binding 1327
Egr-1 1143
 electrochemotherapy 1763
 electromagnetic fields 1939
 electroporation 1763
 endocrine tumours 1746
 endogenous hormones 1394
 endometrial cancer 245, 1175
 endometrial thickness 1175
 endosomal/lysosomal acidification 1327
 endothelial cells 307, 1484
 endothelin 788
 endothelin-1 163
 Ep-CAM 574
 epidemiology 63, 74, 382, 679, 684, 695, 1032, 1370, 1682, 1687, 1698
 epidermal growth factor 796
 epithelial cancers 1501
 epithelial ovarian carcinoma 237
 Epstein-Barr virus 1566
 ErbB2 396
 erythropoietin 988, 1851
 ethnicity 277
E. tirucalli 1566
 Etoposide 25, 132
 Ewing's sarcoma 137
 EWS 137
 exercise 679
 explant 767
 external-beam radiation therapy 645
 extracellular matrix 871, 1248
 extrahepatic bile duct carcinoma 1234
 familial 1256
 Fas 1301
 fascin 537
 FasLigand 788
 febrile neutropenia 181
 FGF8b 1432
 FHIT 1501
 Fhit expression 1213
 fibrin 718
 fibromatosis 645
 fibulin 871
 fine-needle aspiration 354, 699, 702
 FISH 1432, 1587
 Flanders 560
 Fli-1 137
 fluid-based specimen 1883
 fluid-phase/receptor-mediated endocytosis 1327
 fluoropyrimidines 648
 fluorouracil 1017, 1510, 1859
 folic acid 1859
 food additives 940
 formulation 50
 Foscan 283
 Foscan[®] 146
 fotemustine 496
 fragile sites 1501
 fruit 1388
 fruit and vegetables 689
 ftorafur 957
 functional screening 910
 fusion proteins 1622
 γ -radiation 388
 G1/S transition 1417
 G2 arrest 1470
 G₂-M 455
 gallstones 79
 gastric cancer 796, 1560, 1909, 1914
 gastrin-releasing peptide 1808
 gastrointestinal tract 1746
 gelsolin 606
 gemcitabine 491, 1963
 gene amplification 1587
 gene expression profiles 1058
 gene-gene interaction 928
 gene therapy 1492
 genetic counselling 1675
 genetic markers 1740
 genomic instability 548
 genotoxic agents 298
 glioblastoma multiforme 496, 516
 glioma 463, 496, 1277, 1411, 1439
 glutathione 951
 Goseki classification 401
 GPCR 567
 growth factor 1522
 GSK-3 β 1470
 GST genotypes 58
 guidelines 1191
 haem oxygenase 902
 haematogenous dissemination 1900
 haemodialysis 25
 hAG-2 579
 hAG-3 579
 head and neck cancer 1012, 1217, 1740
 health-related quality of life 1185
 health services 1025
 Health Utilities Index 1185
 height 1038
 HeLa 613
HELG 1909
Helicobacter pylori 1239
 hepatic stellate cells 733
 hepatitis viral infection 521
 hepatoblastoma 373
 hepatocellular carcinoma 210, 521, 1878, 1909
 hepatocytes 733
 hepatoma 973
 hepatoma-specific band of serum gamma-glutamyl transferase 1878
 HER-2/neu 1292
 HER2 1032, 1587
 hereditary tumours 1285
 hierarchical clustering 510
 high-dose chemotherapy 1831, 1874
 high-grade osteosarcoma 1925
 hip implants 548
 histidine triad 1501
 histological type 1866
 histology 843
 HIT 1501
 HMG1-C 1406
hMLH1 521
 Hodgkin's disease 1335
 Hoechst 33342 1979
 homing 855
 hormone factor risk 1032
 hormone responsiveness 1071
 HPV 16 serology 1095
 HPV 251, 1213
 HPV testing 42, 1570
hTERT 516
 human Mdm2 636
 human neuroblastoma 1527
 human papillomavirus (HPV) 63, 560, 1713, 1883
 human sterol isomerase 438
 Hybrid Capture II 1883
 hyperammonia 447
 hypermethylation 109, 1560
 hyperthermia 1839
 hypoxia 120, 307, 718, 1065, 1439

- IAPs 1077
 IDN 5390 965
 ifosfamide 1168
 IGF-I 1682
 IGF1 277
 IGFBP-3 1682
 I κ B α 624, 1615
 I κ B kinase- α 1598
 IL-10 1605
 IL-12 1453
 IL-2 320
 ILK 1470, 1755
 image analysis 1439
 image processing 1453
 imatinib 983, 1157
 immunocytochemistry 537
 immunoglobulin gene 593
 immunohistochemistry 231, 726, 1077, 1223, 1234, 1263, 1587, 1598, 1727, 1734
 immunoreactivity 1432
 immunostaining 257
 immunotherapy 175, 348, 1135, 1346, 1641
in situ carcinoma 1375
in situ DNA synthesis 257
in vivo electropermeabilization 1763
 independent prognostic factor 1406
 induction 11, 1339
 inflammation 1207, 1772
 inflammatory breast cancer 718
 iNOS 120
 insulin 263
 insulin-like growth factor-1 277
 insulin-like growth factor-2 733
 interleukin-2 1641
 interleukin 6 630
 interleukin-12 1641
 interstitium 291
 intracellular localisation 146
 intrahepatic cholangio-carcinoma 1894
 intrapleural therapy 1839
 invasion 463, 1631
 invasiveness factors 1207
 ionising radiation 1785, 1800
 irinotecan 335, 1180, 1516
 ischaemia-reperfusion injury 760
 isolated hepatic perfusion 314
- Jak-STAT1 signalling 1995
 Japanese 1038
 Jurkat 455
- Kaposi's sarcoma 1
 kidney 327
 kidney cancer 84
 KOC 699
 KOC RNA binding protein 887
 KRAB 137
 kringles 1-5 1492
 KSHV/HHV-8 1
 Ku80 202
- L1210 613
 lactacystin 120
 LAR 1223
 large bowel cancer 84
 lauryl gallate 940
 LDB1 1543
 leiomyosarcoma 510
 leptomycin B 636
 LIM 1543
 limited proteolysis 636
 linkage analysis 1920
 lip cancer 1702
 lipid droplets 1439
 literature review 63, 1721
 liver metastases 314
 LMO4 1543
 LOH 251, 270, 1578
 long-term survival 496, 1666, 1900
 longitudinal study 689
 loss of heterozygosity (LOH) 420, 1889
 low-dose aspirin 684
 lung cancer 606, 808, 887, 1025, 1229, 1727
 lung resistance-related protein 879
 lymph node 553, 702
 lymph node metastasis 237
 lymphadenopathy 354
 lymphodepletion 1874
 lymphoma 132, 553
 lymphopenia 181
- macromolecule uptake 291
 macrophage inhibitory factor-1 1101
 magnetic resonance imaging 1017, 1135
 magnetic resonance mammography 4
 male and female breast cancer 933
 malignancy 354
 malignant fibrous histiocytoma 510
 malignant melanoma 74, 175, 1358
 malignant mesothelioma 1553
 malignant neoplasms 362
 malignant pleural mesothelioma 167
 mammary carcinoma 1995
 mammography 362
 mannose 6-phosphate/insulin-like growth factor-2 receptor 733
 MAP kinase 748
 marker 1065, 1191
 marker genes 1091
 Markov model 1866
maspin gene expression 863
 mast cells 1157
 matrix metalloproteinases 1318, 1445, 1553
 MCF-7 567, 599, 1310
 MDA-MB-231 cell line 944
 medullary thyroid cancer 1537
- MEK 848
 melanoma 132, 291, 424, 1157, 1381, 1403, 1920
 melphalan 314
 memory T cells 223
 mesothelioma 1839
 mesothelioma cells 388
 meta-analysis 1047, 1191
 metabolism 782
 metastases 702
 metastasis 96, 491, 537
 metastatic breast cancer 1406, 1631, 1669, 1721
 metastatic colorectal cancer 1248
 methylation 217, 413, 463
 MGMT 521
 MHC II 424
 microarray 510, 1995
 microbeam 767
 microcirculation 1462
 microdialysis 782
 microsatellite instability 413
 microsatellite repeats 1740
 microsatellites 1925
 microspectrofluorometry 146
 microtubules 1793
 microvasculature 291
 microvessel density (MVD) 314, 1424, 1900
 midkine 1522
 migration 1484
 minichromosome maintenance (Mcm) proteins 257
 mistletoe lectin 1785
 mitogenesis 567
 mitomycin 1516
 mitosis 1649
 mitotic cell death 1763
 mitoxantrone 491
 MMP-2 1248
 molecular target 1522
 monoclonal antibody 996
 monocytes 1207
 mortality 1047
 mouse fibrosarcoma 760
 MRI 478, 1592
 mRNA 206
 MtDNA 90
 mucositis 1012
 multicentre phase II study 1346
 multidrug resistance 879, 1963
 multidrug resistance-associated protein 1 879
 multiple intestinal neoplasia 1445
 multiple myeloma 855
 multiple skin cancers 1375
 multivariate analysis 1721
 mutant p21 530
 mutations 109, 206, 1271, 1403, 1584, 1909
- N15 antibody 202
 naïve T cells 223
 napsin 1229
 nasopharyngeal carcinoma 187
 N-cadherin 1727
- negative screening 1054
 neoadjuvant chemotherapy 187, 406, 1017, 1339
 neoplasms 988, 1358
 neoplastic cells 918
 neovascularization 102
 nervous system tumours 109
 NESP55 1746
 neuroblastoma 478, 1522, 1641, 1874
 neurokinine receptor antagonists 1823
 neuropilin 796
 neurotoxicity 1942
 nevus density 1920
 NF- κ B 120, 153, 624
 NHEJ 1251
 nitric oxide 902, 1484
 nitroimidazole 307
 NK₁ antagonists 1823
 non-Hodgkin's lymphoma 74, 1335
 nonplatinum regimen 342
 non-small-cell lung cancer 231, 335, 537, 814, 1666
 nonviral vectors 1641
 normal prostate NPTX 1532 cells 1605
 Northern Ireland 1256
 NSAIDs 803, 1687
 nuclear factor- κ B 1598
 nuclear localisation 115
- ODC 1143
 oesophageal cancer 18, 1095, 1549
 oesophageal squamous cell cancer 115, 1217, 1734
 oestrogen 50
 oestrogen receptor 579, 871, 1071
 oncological interviews 502
 oral 648
 oral contraceptives 50, 1713
 oral leukoplakia 366
 oral route 965
 oral squamous cell carcinoma 1105
 oral submucous fibrosis 366
 ornithine 613
 ornithine cycle 447
 oropharyngeal carcinoma 1095
 osteoclast 1318
 osteosarcoma 396, 1995
 ovarian cancer 470, 654, 666, 839, 848, 1780
 ovary 1828
 oxaliplatin 1942
 oxidative stress 902
 oxygen 1462
- p14 217
 p16 217
 p21 protein 754
 p21^{ras} 1971
 p27^{KIP1} 1277
 p53 251, 298, 636, 1281, 1310, 1492, 1649, 1785, 1925

- p53 gene 1271, 1740
p53 protein 754, 1793
p63 740
paan chewing 1388
paclitaxel 1285, 1649, 1942
paediatric population 1925
PAI-1 96
pancreas 1746
pancreatic cancer 217, 530, 679, 1180, 1971
pancreatitis 217
parental smoking 373
pathology 654
patient 1119
patient information 1661
patient-physician relationship 658
pediatric 1185
penile carcinoma 1095
pepsinogen 1239
peptide vaccination 530
perfusion 291, 1439, 1979
perilesional skin 90
peripheral blood progenitor cell transplantation 1831
peritoneal cytology 245
PF regimens 11
pharmacodynamics 1160
pharmacokinetics 283, 782, 814, 1160, 1942
phase I study 1128, 1168, 1844
phase I/II study 491
phase II 648
phenylacetate carboxymethyl benzylamide dextran (NaPaC) 1987
Phortress 470
phosphohistone H3 257
phosphoinositides 606
photodynamic diagnosis 1780
photodynamic therapy (PDT) 283, 432, 760, 1772
physical activity 679
physicians' locus of control 502
PKC 606, 748
plasminogen 1492
plasminogen activation inhibitor type 2 944
platinum 1128
platinum DNA adducts 814
pleural malignancies 1839
PMN-elastase 1084
polymerase chain reaction 1883
polymorphism 263, 928
population-based cohort study 382
population mixing 1370
prediction 1091
predictive markers 406
predisposing 988
prevention 1687
primary cells 1071
primary liver carcinoma 1894
progesterin 50
prognosis 18, 102, 237, 348, 516, 537, 574, 593, 726, 1065, 1191, 1549, 1553
prognostic factors 1199, 1510, 1537
prognostic markers 31, 115, 586, 1077
prognostic value 401, 863
prolactin 1301
prolactin receptor 1301
proliferation 613, 767, 1143, 1484
proliferation inhibition 438
prophylactic mastectomy 1675
prophylaxis 1507
prospective study 1394
prostaglandin E₂ 630
prostate cancer 31, 195, 263, 822, 928, 1101, 1358, 1432, 1615, 1682
proteasome 636
protein 1417
protein induced by vitamin K absence or antagonist II 1878
protein kinase C alpha 1400
protein tyrosine kinase inhibitors 940
protein-tyrosine kinase 1058
proteolysis 871
protoporphyrin IX 1462
protracted intravenous infusion 1859
Pseudomonas exotoxin 1327
psychological stress 1698
psychosocial impact 42
PTHRP 567
PTP 1223
pyridinoline 1105
quality of life 988
quantitative RT-PCR 1101
quinazolines 1615
radiation 487
radiosensitivity 120, 1470, 1251
radiotherapy 187, 828, 1012, 1017, 1025, 1251, 1352, 1584
radiotherapy fractionation 711
railways 695
raltitrexed 1180
randomised phase III trial 335
rat fibroblasts 1956
RAY1 1909
Rb 1925
RBI gene 109
real-time PCR 516, 1091
real-time RT-PCR quantification 863
receptor 1119
receptor radiotherapy 645
recombinant fusion proteins 937
records 839
relapse-free survival 1537
relative risk 1054
renal-cell carcinoma (RCC) 348, 1346, 1417, 1516, 1800
renal insufficiency 25
repressor 137
resection margin 1549
residual neoplasms 843
response biomarker 1592
response to therapy 1084
retinoic acid 1058
retinol 1381
retrovirus 1119
RhoA 1631
risk 348, 684, 1687
risk factors 79, 181, 366, 672, 1702
risk model 181
risk perception 1675
ruthenium(III) 1484
S-1 648
S-phase arrest 599
Sant 7 630
Scotland 1256
SDF-1 1631
seasonal variation 1358
second-line treatment 1180, 1828
self-efficacy 658
senescence 463
sequential-triplet chemotherapy 342
sex behaviour 666
sex ratio in offspring 382
sigma receptors 438
signal transduction 796, 1281
signal transduction pathways 1800
signalling 153
silicone 832
single nucleotide polymorphism 1734
skin cancer 90
Smad 1615
Smad4 420
smoking 366
soft tissue sarcoma 510
solid tumours 1831
soluble CD105 1424
somatic hypermutation 593
somatostatin 132
South Africa 1361
SP-G 1808
specialisation 1708
spectroscopy 478
spermatogonia 828
spheroid model 463
sporadic breast cancer 1263
squamous cell carcinoma 63
squamous cell carcinoma of the head and neck 11
SR31747A 438
ST7 1909
staging 1105
standardised incidence ratio 1666
standardised mortality ratio 1666
statistical methods 1693
statistical models 843
stratification 348
substance P 1823
substance P analogues 1808
sun exposure 1702
surfactant protein 1229
surgery 1025, 1549
survival 348, 1025, 1693, 1698, 1708
survival-analysis 102, 1191
survival rate 1721
survivin 1077
survivin expression 115
synovial sarcoma 510
synthesis 1948
systematic review 1191
tamoxifen 1084, 1175
tamoxifen resistance 1400
tandem duplications 90
targeted α therapy 944
targeting 1622
taxanes 965, 1339
Taxol 973
T-cell homeostatic proliferation 1874
T-cells 530
TCF 1932
telomere length 593
temozolomide 175
tenascin 996
testicular biopsy 828
testicular cancer 36
testicular germ-cell tumours 879
testicular intraepithelial neoplasia 828
testicular neoplasms 828
testis 843
TGF- β 1 1615
TGF β 420, 1424
thalidomide 822
therapeutic vaccine 887
thymidine kinase 1963
thymidine phosphorylase 957
thymidine phosphorylase inhibitor 957
thyroid cancer 1223, 1358
TIL 320
time course 1510
time-lapse microscopy 1310
TIMP-1 1248, 1605
tissue exposure 782
tissue microarray 231, 1417
T lymphocyte 1119
TNF- α 314
tobacco 1702
tocopherol 1381
tomudex 624
topoisomerase I 1310
topoisomerase I inhibitor 808
topoisomerase II α 455
topoisomerase II inhibitor 808
topotecan 1310
toxicity 181, 1160, 1199, 1831
TP53 848
TRAIL 153, 298, 910, 918, 1800
TRAIL receptors 298
transport mechanisms 291
transporter 951
transvaginal ultrasonography 1175
trifluorothymidine 957

- TT-232 132
TTF-1 1229
tumor antigen 887
tumorigenesis 420
tumour angiogenesis 1987
tumour delivery 1979
tumour growth 163, 902, 1111, 1808
tumour immunosuppression 320
tumour marker 396, 699, 1522, 1894
tumour metastasis 327
tumour perfusion 1592
tumour response 406
tumour suppression 606
tumour suppressor 1411, 1501
- tumour-suppressor gene 1909
tumour targeting 937
tyrosine phosphorylation 1605
- ultrasound 354, 702
uPA 96
upper aerodigestive tract cancer 672
urea/bisulphite sequencing 521
urinary sex steroids 1394
urothelium 740, 767
- vaginal and vulvar cancer 1095
validity 843
vascular damage 283
vascular endothelial growth factor (VEGF) 796, 1987
- vascular phenotype 553
vascular regression 553
vascular targeting agents 1592
vegetables 1388
VEGF 1622
VEGF-C 237
VEGF-D 237
VEGFR-3 237, 1453
VIN 251
vinorelbine 1281
viral gene expression 1566
visible reflectance spectroscopy 760
vitamin D receptor 928
vitamin E analogues 1948
vitamin E succinate 153
vulval cancer 251
- vulval intraepithelial neoplasia (VIN) 257
- warts 1702
weekly chemotherapy 808
women 1381
- X-rays 447
xanthine oxidase 760
xenograft 478
- ζ chain 223
ZD6126 1592
zoledronate 1971
zoledronic acid 1971
zometa 1971